LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 466

Search options

  1. Book: Co-infection VHC-VIG

    Pol, Stanislas

    du protocole RIBAVIC à la pratique quotidienne

    (Gastroentérologie clinique et biologique ; 33, Suppl. 2)

    2009  

    Title variant HCV-HIV co-infection
    Author's details coord.: S. Pol
    Series title Gastroentérologie clinique et biologique ; 33, Suppl. 2
    Collection
    Language French
    Size S. S92 - S119 : graph. Darst.
    Publisher Elsevier-Masson
    Publishing place Issy-les-Moulineaux
    Publishing country France
    Document type Book
    HBZ-ID HT015910170
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Article ; Online: Withdrawal of Nucleos(t)ide Analogues in the Treatment of Chronic Hepatitis B: A Cornelian Choice.

    Pol, Stanislas

    Gastroenterology

    2021  Volume 162, Issue 3, Page(s) 698–699

    MeSH term(s) Hepatitis B e Antigens ; Hepatitis B virus/genetics ; Hepatitis B, Chronic/diagnosis ; Hepatitis B, Chronic/drug therapy ; Humans
    Chemical Substances Hepatitis B e Antigens
    Language English
    Publishing date 2021-12-14
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 80112-4
    ISSN 1528-0012 ; 0016-5085
    ISSN (online) 1528-0012
    ISSN 0016-5085
    DOI 10.1053/j.gastro.2021.12.240
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: La révolution thérapeutique de l’hépatite C honorée par un prix Nobel.

    Pol, Stanislas

    La Revue du praticien

    2021  Volume 70, Issue 9, Page(s) 935–941

    Title translation The therapeutic revolution of hepatitis C virus infection honored by a Nobel prize.
    MeSH term(s) Hepacivirus ; Hepatitis C/drug therapy ; History, 20th Century ; Humans ; Nobel Prize
    Language French
    Publishing date 2021-03-19
    Publishing country France
    Document type Historical Article ; Journal Article
    ZDB-ID 205365-2
    ISSN 2101-017X ; 0035-2640
    ISSN (online) 2101-017X
    ISSN 0035-2640
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Similar 5-year HCC occurrence in Tenofovir- and Entecavir-treated HBV chronic infection in the French AFEF/ANRS CO22 Hepather cohort.

    Pol, Stanislas

    Alimentary pharmacology & therapeutics

    2021  Volume 53, Issue 5, Page(s) 616–629

    Abstract: Background: Chronic hepatitis B virus (HBV) infection results in a high risk of cirrhosis and its complications, cirrhosis decompensation (DC), hepatocellular carcinoma (HCC), liver transplantation (LT), death or any of these outcomes (composite ... ...

    Abstract Background: Chronic hepatitis B virus (HBV) infection results in a high risk of cirrhosis and its complications, cirrhosis decompensation (DC), hepatocellular carcinoma (HCC), liver transplantation (LT), death or any of these outcomes (composite endpoint [CE]). Nucleos(t)ide analogues (NUCs) such as tenofovir or entecavir are associated with a reduction in these complications.
    Aim: To compare the impact of tenofovir and entecavir on these outcomes in patients treated for HBV infection and included in the prospective Hepather cohort.
    Methods: All patients with HBV infection who had received tenofovir or entecavir for more than 6 months at or after entry in the ANRS CO22 cohort were selected. Patients with HDV and HCV co-infection or prior liver event were excluded. Incidence rates of events were compared using inverse probability of treatment weighting (IPW).
    Results: The cohort included 1800 patients (986 tenofovir and 814 entecavir). Median follow-up was 4.2 years. The incidences of HCC, DC, LT, ACD, LRD and CE were not different between tenofovir- (1.8 (0.9; 3.2), 0.6 (0.2; 1.6), 0.2 (0.0; 0.8), 1.7 (0.8; 3.0), 0.8 (0.2, 1.8) and 4.1 (3.0; 5.4) per 1000 person-years) and entecavir-treated patients (1.6 (0.7; 3.0), 0.7 (0.2; 1.8), 0.2 (0.0; 1.0), 3.0 (1.7, 4.8), 0.5 (0.1; 1.5) and 5.0 (3.3; 7.2)) per 1000 person-years, respectively.
    Conclusion: The risk of liver-related events or death was not different between tenofovir- and entecavir-treated patients in this large prospective cohort of predominantly non-cirrhotic French patients.
    Trial registration number: NCT019553458.
    MeSH term(s) Antiviral Agents/adverse effects ; Carcinoma, Hepatocellular/drug therapy ; Carcinoma, Hepatocellular/epidemiology ; Guanine/analogs & derivatives ; Hepatitis B virus ; Hepatitis B, Chronic/drug therapy ; Hepatitis B, Chronic/epidemiology ; Humans ; Liver Neoplasms/drug therapy ; Liver Neoplasms/epidemiology ; Prospective Studies ; Tenofovir/adverse effects ; Treatment Outcome
    Chemical Substances Antiviral Agents ; entecavir (5968Y6H45M) ; Guanine (5Z93L87A1R) ; Tenofovir (99YXE507IL)
    Language English
    Publishing date 2021-01-19
    Publishing country England
    Document type Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 639012-2
    ISSN 1365-2036 ; 0269-2813 ; 0953-0673
    ISSN (online) 1365-2036
    ISSN 0269-2813 ; 0953-0673
    DOI 10.1111/apt.16197
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Hépatites virales : messages clés.

    Pol, Stanislas

    La Revue du praticien

    2019  Volume 68, Issue 3, Page(s) 293

    Title translation Hepatitis virus infection: key messages.
    MeSH term(s) Hepatitis B ; Hepatitis C ; Hepatitis Viruses ; Humans
    Language French
    Publishing date 2019-04-03
    Publishing country France
    Document type Journal Article
    ZDB-ID 205365-2
    ISSN 2101-017X ; 0035-2640
    ISSN (online) 2101-017X
    ISSN 0035-2640
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Virus de l’hépatite C : une élimination programmable.

    Pol, Stanislas

    Presse medicale (Paris, France : 1983)

    2019  Volume 48, Issue 1 Pt 1, Page(s) 1–3

    Title translation Elimination of hepatitis C virus infection.
    MeSH term(s) Disease Eradication ; Hepatitis C, Chronic/prevention & control ; Humans
    Language French
    Publishing date 2019-02-19
    Publishing country France
    Document type Editorial
    ZDB-ID 120943-7
    ISSN 2213-0276 ; 0032-7867 ; 0755-4982 ; 0301-1518
    ISSN (online) 2213-0276
    ISSN 0032-7867 ; 0755-4982 ; 0301-1518
    DOI 10.1016/j.lpm.2019.01.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Hépatites virales : vacciner et dépister !

    Pol, Stanislas

    La Revue du praticien

    2019  Volume 68, Issue 3, Page(s) 267–268

    Title translation Viral hepatitis: vaccinate and screen?
    MeSH term(s) Hepatitis B/prevention & control ; Hepatitis B Vaccines/therapeutic use ; Humans ; Vaccination
    Chemical Substances Hepatitis B Vaccines
    Language French
    Publishing date 2019-04-03
    Publishing country France
    Document type Journal Article
    ZDB-ID 205365-2
    ISSN 2101-017X ; 0035-2640
    ISSN (online) 2101-017X
    ISSN 0035-2640
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Éditorial.

    Pol, Stanislas

    Presse medicale (Paris, France : 1983)

    2019  Volume 48, Issue 12, Page(s) 1457–1458

    Title translation Editorial.
    MeSH term(s) Bariatric Surgery ; Biopsy ; Comorbidity ; Humans ; Liver/pathology ; Liver Cirrhosis/complications ; Liver Cirrhosis/pathology ; Non-alcoholic Fatty Liver Disease/epidemiology ; Non-alcoholic Fatty Liver Disease/etiology ; Non-alcoholic Fatty Liver Disease/mortality ; Obesity/complications ; Obesity/surgery ; Severity of Illness Index
    Language French
    Publishing date 2019-11-30
    Publishing country France
    Document type Editorial
    ZDB-ID 120943-7
    ISSN 2213-0276 ; 0032-7867 ; 0755-4982 ; 0301-1518
    ISSN (online) 2213-0276
    ISSN 0032-7867 ; 0755-4982 ; 0301-1518
    DOI 10.1016/j.lpm.2019.11.004
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: L’hépatite C face au défi de la guérison.

    Pol, Stanislas

    La Revue du praticien

    2019  Volume 68, Issue 3, Page(s) 269–275

    Abstract: Hepatitis C facing the challenge of healing. Hepatitis C virus (HCV) infection affects 71 million people worldwide. It is a systemic disease associating hepatic manifestations, extra-hepatic manifestations by cryoglobulinemic vasculitis and general ... ...

    Title translation Hepatitis C facing the challenge of healing.
    Abstract Hepatitis C facing the challenge of healing. Hepatitis C virus (HCV) infection affects 71 million people worldwide. It is a systemic disease associating hepatic manifestations, extra-hepatic manifestations by cryoglobulinemic vasculitis and general manifestations related to chronic inflammation (diabetes, cardio-, reno- or cerebrovascular manifestations and extrahepatic cancers including non-Hodgkin's lymphoma). The significant morbidity and mortality related to HCV therefore justifies its screening, access to treatments that have significantly increased over the past two decades. Understanding the replicative cycle of HCV allowed indeed the development of HCV-specific direct antivirals targeting viral proteins (NS3/4A protease, NS5B polymerase with nucleos(t)idic inhibitors, NS5A multifunctional replication complex protein). The combination of two to three specific inhibitors, sometimes coformulated in a single tablet regimen, without pegylated interferon and most often without ribavirin, allows a high antiviral efficacy (more than 95% cure) for treatment durations of 8 to 12 weeks with a satisfactory tolerance. HCV infection is the only chronic infection that can be cured and hepatic or extrahepatic manifestations are mostly reversible. It underscores the importance of strengthening screening and access to care policies to hope for the elimination of viral C infection in the short term.
    MeSH term(s) Adult ; Antiviral Agents/therapeutic use ; Child ; Drug Therapy, Combination ; Hepacivirus ; Hepatitis C/drug therapy ; Humans ; Ribavirin
    Chemical Substances Antiviral Agents ; Ribavirin (49717AWG6K)
    Language French
    Publishing date 2019-04-03
    Publishing country France
    Document type Journal Article
    ZDB-ID 205365-2
    ISSN 2101-017X ; 0035-2640
    ISSN (online) 2101-017X
    ISSN 0035-2640
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Is stronger better in curing hepatitis C virus infection?

    Pol, Stanislas

    Annals of translational medicine

    2016  Volume 4, Issue 19, Page(s) 386

    Language English
    Publishing date 2016-10-25
    Publishing country China
    Document type Journal Article ; Comment
    ZDB-ID 2893931-1
    ISSN 2305-5847 ; 2305-5839
    ISSN (online) 2305-5847
    ISSN 2305-5839
    DOI 10.21037/atm.2016.08.26
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top